• Na Zhang, Hui Wang, Wenwen Sun, Hou Hou, Jun Du, Jiaojiao Xu, and Wei Wei.
• Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin 300052, China; Tianjin Clinical Research Center for Rheumatic and Immune Diseases, Tianjin 300052, China.
• Med Clin (Barc). 2024 Jan 12; 162 (1): 181-8.

BackgroundILD is a common manifestation in pSS and is associated with an increased risk of death. APCA are strongly expressed by hyperplastic alveolar epithelial cells in the fibrotic lung and are associated with an accelerated decline in lung function in IPF. In the present study, we aimed to evaluate the clinical utility of APCA in ILD patients with pSS.MethodsClinical, laboratory, PFTs and imaging data from pSS patients were reviewed, and the ESSDAI was utilized to evaluate disease activity. HRCT semiquantitative scoring was conducted. We compared the clinical characteristics of pSS patients with and without ILD and carried out logistic regression analysis of risk factors for ILD in pSS.ResultsA total of 74 patients with pSS and 40 HCs were included in the study. ILD was more commonly observed in the APCA-positive group than in the APCA-negative group. The quantitative levels of APCA were positively correlated with the imaging score. Multivariate analysis found that the long disease duration, elevated APCA and elevated KL-6 level were independent risk factors for ILD in pSS patients. The area under ROC curve for APCA was 0.6618, and the threshold concentration was 153.82ng/ml (sensitivity 45.24%, specificity 87.50%).ConclusionAPCA level is an independent risk factor and might be a potential biomarker for ILD in patients with pSS.Copyright © 2023. Published by Elsevier España, S.L.U.

20 keywords...

hide…